Haemonetics Interest Income from 2010 to 2026

HAE Stock

USD 59.50 0.01 0.02%

Haemonetics' Interest Income is increasing over recent years with slightly volatile volatility. It is projected to reach approximately 13.2 M this year. Interest Income is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. View All Fundamentals

Interest Income

First Reported

2019-06-30

Previous Quarter

7.2 M

Current Value

7.4 M

Quarterly Volatility

2.2 M

Macro event markers

Covid

Interest Hikes

Review Haemonetics financial statements over time to add context on performance and capital structure. Key drivers include Interest Expense of 13.7 M, Total Revenue of 1.6 B or Gross Profit of 940.1 M along with ratios such as Price To Sales Ratio of 2.14, Dividend Yield of 0.0098 or PTB Ratio of 2.81. This view complements Haemonetics Valuation and Volatility modules.

Build AI portfolio with Haemonetics Stock

Review Haemonetics Correlation against competitors for Haemonetics. This adds peer-relative context.

For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.

Analyzing Haemonetics's Interest Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Interest Income has evolved provides context for assessing Haemonetics's current valuation and future prospects.

Latest Haemonetics' Interest Income Growth Pattern

Below is the plot of the Interest Income of Haemonetics over the last few years. It is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. Haemonetics' Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Haemonetics' overall financial position and show how it may be relating to other accounts over time.

Interest Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Interest Income

Timeline

Haemonetics Interest Income Regression Statistics

	Arithmetic Mean	11,251,932
	Geometric Mean	10,737,709
	Coefficient Of Variation	30.34
	Mean Deviation	2,757,806
	Median	9,746,000
	Standard Deviation	3,413,803
	Sample Variance	11.7T
	Range	12.6M
	R-Value	0.48
	Mean Square Error	9.5T
	R-Squared	0.23
	Significance	0.05
	Slope	327,504
	Total Sum of Squares	186.5T

Haemonetics Interest Income History

	2026	13.2 M
	2025	11.2 M
	2024	9.7 M
	2023	13 M
	2022	14.6 M
	2021	17.1 M
	2020	16.8 M

Other Fundumenentals of Haemonetics

Net Interest Income

Haemonetics Interest Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Short Term Investments	Common Stock	Long Term Debt	Good Will	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Accumulated Depreciation	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.56	0.93	0.38	0.91	0.63	0.98	0.98	0.71	0.97	-0.41	0.45	0.95	0.98	0.53	0.59	-0.77	0.96	0.69	0.61	-0.17	-0.14	0.74	0.59	0.68	-0.74
Total Stockholder Equity	0.56		0.3	0.71	0.64	0.87	0.41	0.57	0.12	0.51	-0.8	0.61	0.41	0.52	0.79	0.01	-0.43	0.43	0.48	0.46	-0.58	-0.29	0.35	0.36	0.27	-0.01
Net Debt	0.93	0.3		0.15	0.77	0.45	0.98	0.88	0.74	0.94	-0.12	0.4	0.97	0.95	0.4	0.77	-0.8	0.97	0.66	0.61	0.0	-0.1	0.76	0.62	0.7	-0.78
Retained Earnings	0.38	0.71	0.15		0.33	0.49	0.23	0.37	0.12	0.41	-0.52	0.16	0.24	0.35	0.38	-0.15	-0.04	0.25	-0.16	0.38	-0.16	0.25	0.11	0.41	-0.21	-0.16
Accounts Payable	0.91	0.64	0.77	0.33		0.75	0.86	0.92	0.6	0.82	-0.54	0.55	0.81	0.86	0.66	0.53	-0.65	0.82	0.76	0.42	-0.34	-0.25	0.64	0.5	0.69	-0.59
Net Receivables	0.63	0.87	0.45	0.49	0.75		0.53	0.65	0.29	0.52	-0.66	0.66	0.51	0.55	0.84	0.25	-0.42	0.52	0.59	0.36	-0.47	-0.28	0.51	0.57	0.43	-0.16
Total Liab	0.98	0.41	0.98	0.23	0.86	0.53		0.95	0.76	0.96	-0.24	0.39	0.97	0.98	0.44	0.68	-0.79	0.98	0.69	0.61	-0.04	-0.1	0.8	0.61	0.73	-0.78
Total Current Assets	0.98	0.57	0.88	0.37	0.92	0.65	0.95		0.73	0.92	-0.48	0.38	0.9	0.94	0.48	0.49	-0.71	0.91	0.66	0.55	-0.16	-0.08	0.74	0.55	0.67	-0.75
Short Term Debt	0.71	0.12	0.74	0.12	0.6	0.29	0.76	0.73		0.68	-0.1	0.18	0.61	0.67	0.21	0.58	-0.39	0.61	0.37	0.13	0.18	0.22	0.71	0.58	0.3	-0.81
Intangible Assets	0.97	0.51	0.94	0.41	0.82	0.52	0.96	0.92	0.68		-0.31	0.4	0.95	0.99	0.45	0.6	-0.8	0.96	0.6	0.69	-0.09	-0.04	0.7	0.6	0.62	-0.72
Short Term Investments	-0.41	-0.8	-0.12	-0.52	-0.54	-0.66	-0.24	-0.48	-0.1	-0.31		-0.52	-0.19	-0.3	-0.64	0.14	0.26	-0.21	-0.35	-0.08	0.73	0.35	-0.07	0.02	-0.08	0.02
Common Stock	0.45	0.61	0.4	0.16	0.55	0.66	0.39	0.38	0.18	0.4	-0.52		0.39	0.42	0.84	0.58	-0.55	0.4	0.62	0.18	-0.67	-0.53	0.26	0.15	0.27	0.0
Long Term Debt	0.95	0.41	0.97	0.24	0.81	0.51	0.97	0.9	0.61	0.95	-0.19	0.39		0.97	0.43	0.68	-0.83	1.0	0.66	0.72	-0.06	-0.14	0.75	0.57	0.76	-0.72
Good Will	0.98	0.52	0.95	0.35	0.86	0.55	0.98	0.94	0.67	0.99	-0.3	0.42	0.97		0.47	0.62	-0.84	0.98	0.67	0.7	-0.12	-0.11	0.75	0.57	0.7	-0.7
Property Plant Equipment	0.53	0.79	0.4	0.38	0.66	0.84	0.44	0.48	0.21	0.45	-0.64	0.84	0.43	0.47		0.41	-0.4	0.44	0.65	0.24	-0.6	-0.6	0.37	0.42	0.33	-0.07
Current Deferred Revenue	0.59	0.01	0.77	-0.15	0.53	0.25	0.68	0.49	0.58	0.6	0.14	0.58	0.68	0.62	0.41		-0.57	0.67	0.54	0.22	-0.04	-0.21	0.51	0.42	0.46	-0.55
Net Tangible Assets	-0.77	-0.43	-0.8	-0.04	-0.65	-0.42	-0.79	-0.71	-0.39	-0.8	0.26	-0.55	-0.83	-0.84	-0.4	-0.57		-0.84	-0.73	-0.73	0.34	0.29	-0.61	-0.21	-0.73	0.34
Long Term Debt Total	0.96	0.43	0.97	0.25	0.82	0.52	0.98	0.91	0.61	0.96	-0.21	0.4	1.0	0.98	0.44	0.67	-0.84		0.67	0.72	-0.08	-0.15	0.75	0.57	0.76	-0.71
Capital Surpluse	0.69	0.48	0.66	-0.16	0.76	0.59	0.69	0.66	0.37	0.6	-0.35	0.62	0.66	0.67	0.65	0.54	-0.73	0.67		0.36	-0.38	-0.65	0.6	0.29	0.85	-0.29
Deferred Long Term Liab	0.61	0.46	0.61	0.38	0.42	0.36	0.61	0.55	0.13	0.69	-0.08	0.18	0.72	0.7	0.24	0.22	-0.73	0.72	0.36		0.01	-0.03	0.56	0.38	0.57	-0.26
Accumulated Depreciation	-0.17	-0.58	0.0	-0.16	-0.34	-0.47	-0.04	-0.16	0.18	-0.09	0.73	-0.67	-0.06	-0.12	-0.6	-0.04	0.34	-0.08	-0.38	0.01		0.54	0.13	0.28	-0.1	-0.39
Short Long Term Debt	-0.14	-0.29	-0.1	0.25	-0.25	-0.28	-0.1	-0.08	0.22	-0.04	0.35	-0.53	-0.14	-0.11	-0.6	-0.21	0.29	-0.15	-0.65	-0.03	0.54		-0.01	0.16	-0.42	-0.2
Cash And Equivalents	0.74	0.35	0.76	0.11	0.64	0.51	0.8	0.74	0.71	0.7	-0.07	0.26	0.75	0.75	0.37	0.51	-0.61	0.75	0.6	0.56	0.13	-0.01		0.59	0.67	-0.56
Net Invested Capital	0.59	0.36	0.62	0.41	0.5	0.57	0.61	0.55	0.58	0.6	0.02	0.15	0.57	0.57	0.42	0.42	-0.21	0.57	0.29	0.38	0.28	0.16	0.59		0.31	-0.55
Net Working Capital	0.68	0.27	0.7	-0.21	0.69	0.43	0.73	0.67	0.3	0.62	-0.08	0.27	0.76	0.7	0.33	0.46	-0.73	0.76	0.85	0.57	-0.1	-0.42	0.67	0.31		-0.4
Capital Stock	-0.74	-0.01	-0.78	-0.16	-0.59	-0.16	-0.78	-0.75	-0.81	-0.72	0.02	0.0	-0.72	-0.7	-0.07	-0.55	0.34	-0.71	-0.29	-0.26	-0.39	-0.2	-0.56	-0.55	-0.4

Click cells to compare fundamentals

Stock Overview, Methodology & Data Sources

Haemonetics Corporation, a healthcare company, provides medical products and solutions. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts. Haemonetics Corp operates under Medical Instruments Supplies classification in the United States and is traded on New York Stock Exchange. It employs 2821 people. The stock overview for Haemonetics summarizes business drivers, financial profile, and market behavior. The company is positioned within Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care. Current metrics include P/E of 50.35, P/B of 3.09, profit margin of 13.31%. Haemonetics has a market cap of 2.84 B, P/E of 50.35, ROE of 19.3%.

Methodology

Unless otherwise specified, financial data for Haemonetics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Haemonetics (USA Stocks:HAE) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Macroaxis analytics incorporate public filings and market reference sources and official disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Food & Drug Administration (FDA). Data harmonization may result in minor timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.

Analyst Sources

Haemonetics is covered by 11 analysts. 5 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Goldman Sachs, UBS Investment Research, Bank of America Securities, RBC Capital Markets, Jefferies, J.P. Morgan, among others. Updates may occur throughout the day.

This content is curated and reviewed by:

Raphi Shpitalnik - Junior Member of Macroaxis Editorial Board

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

MSFT	Microsoft
C	Citigroup
WD	Walker Dunlop

More Resources for Haemonetics Stock Analysis

A structured review of Haemonetics often starts with core financial statements and trend context. Key ratios help frame profitability, efficiency, and growth context for Haemonetics Stock. Outlined below are key reports that provide context for Haemonetics Stock:

How To Invest In Haemonetics

Details

Is Haemonetics Stock a good investment?

Details

What is Haemonetics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Review Haemonetics Correlation against competitors for Haemonetics. This adds peer-relative context.

For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.

Analysis related to Haemonetics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Quarterly Earnings Growth

0.284

Earnings Share

3.63

Revenue Per Share

27.509

Quarterly Revenue Growth

-0.03

Return On Assets

0.0645

The market value of Haemonetics is measured differently than book value, which reflects Haemonetics accounting equity. Haemonetics' market capitalization is 2.84 B. With a P/B ratio of 3.09, the market values Haemonetics well above its book equity. Enterprise value stands at 3.68 B. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.

Note that Haemonetics' intrinsic value and market price are different measures derived from different inputs. For Haemonetics, key inputs include a P/E ratio of 50.35, a P/B ratio of 3.09, a profit margin of 13.31%, and ROE of 19.3%. By contrast, market price reflects the level where buyers and sellers transact.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Haemonetics Interest Income from 2010 to 2026

Latest Haemonetics' Interest Income Growth Pattern

Haemonetics Interest Income Regression Statistics

Haemonetics Interest Income History

Other Fundumenentals of Haemonetics

Haemonetics Interest Income component correlations

Stock Overview, Methodology & Data Sources

Methodology

Analyst Sources

This content is curated and reviewed by:

Also Currently Popular

More Resources for Haemonetics Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY